Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for rheumatoid arthritis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Rituximab (Truxima) - Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or RheumatoidArthritis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity
Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoidarthritis: 72-week data from a randomized Phase 3 trial To evaluate the efficacy and safety of CT-P10, a rituximab biosimilar after a single switch, during a multinational, randomized, double-blind Phase 3 trial involving patients with RA.Patients received 48 weeks' treatment with CT-P10 or United States- or European Union-sourced reference rituximab (US-RTX and EU-RTX, respectively). Patients entering
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe RheumatoidArthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. Patients with active rheumatoidarthritis (RA) despite treatment with biologic disease-modifying antirheumatic drug (bDMARD) therapy need treatment options.To evaluate the effects of filgotinib vs placebo on the signs and symptoms of RA in a treatment-refractory population.A 24-week
Upadacitinib as monotherapy in patients with active rheumatoidarthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Upadacitinib, an oral Janus kinase (JAK)1-selective inhibitor, showed efficacy in combination with stable background conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with rheumatoidarthritis who had an inadequate response to DMARDs. We aimed to evaluate the safety (...) and efficacy of upadacitinib monotherapy after switching from methotrexate versus continuing methotrexate in patients with inadequate response to methotrexate.SELECT-MONOTHERAPY was conducted at 138 sites in 24 countries. The study enrolled adults (≥18 years) who fulfilled the 2010 American College of Rheumatology (ACR)-European League Against Rheumatism (EULAR) classification criteria for rheumatoidarthritis. Patients with active rheumatoidarthritis despite stable methotrexate were randomly assigned 2:2
2019LancetControlled trial quality: predicted high
Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoidarthritis: systematic review and meta-analysis of randomised controlled trials To investigate the effect of Janus kinase inhibitors (Jakinibs) on cardiovascular risk in adult patients with rheumatoidarthritis (RA) via a meta-analysis of randomised controlled trials (RCTs).PubMed, Embase and Cochrane library were thoroughly searched for RCTs reporting safety issues in patients with RA receiving
How do biosimilar medications compare to their corresponding originator biologic medications in treating patients with conditions like rheumatoidarthritis or inflammatory bowel disease? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives (...) for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca May 27, 2019 It’s all in the details... or is it? Biosimilars versus biologics for inflammatory conditions. Clinical Question: How do biosimilar medications compare to their corresponding originator biologic medications in treating patients with conditions like rheumatoidarthritis or inflammatory bowel disease? Bottom Line: For patients with rheumatoidarthritis, other inflammatory
Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoidarthritis in patients with low disease activity. Anti-tumour necrosis factor (TNF) agents are effective in treating people with rheumatoidarthritis (RA), but are associated with (dose-dependent) adverse effects and high costs. To prevent overtreatment, several trials have assessed the effectiveness of down-titration compared with continuation of the standard dose. This is an update
Risk of Biologics and Glucocorticoids in Patients With RheumatoidArthritis Undergoing Arthroplasty: A Cohort Study. Patients with rheumatoidarthritis (RA) are at increased risk for infection after arthroplasty, yet risks of specific biologic medications are unknown.To compare risk for postoperative infection among biologics and to evaluate the risk associated with glucocorticoids.Retrospective cohort study.Medicare and Truven MarketScan administrative data from January 2006 through September
Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoidarthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase To evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoidarthritis (RA).This was a multi-centre, randomised
Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoidarthritis: first-year results of the randomised controlled TARA study The aim of this study is to evaluate the effectiveness of two tapering strategies after achieving controlled disease in patients with rheumatoidarthritis (RA), during 1 year of follow-up.In this multicentre single-blinded (research nurses) randomised controlled trial, patients with RA were
Adalimumab (Idacio) - Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Psoriasis, Arthritis, Psoriatic, Spondylitis, Ankylosing, Uveitis, Hidradenitis Suppurativa, Colitis, Ulcerative, Crohn Disease EMA/85985/2019 EMEA/H/C/004475 Idacio (adalimumab) An overview of Idacio and why it is authorised in the EU What is Idacio and what is it used for? Idacio is a medicine that acts on the immune system (the body’s natural defences) and is used to treat the following conditions: • plaque (...) psoriasis (a disease causing red, scaly patches on the skin); • psoriatic arthritis (a disease causing red, scaly patches on the skin with inflammation of the joints); • rheumatoidarthritis (a disease causing inflammation of the joints); • axial spondyloarthritis (inflammation of the spine causing back pain), including ankylosing spondylitis and when there are clear signs of inflammation but X-ray does not show disease; • polyarticular juvenile idiopathic arthritis and active enthesitis-related
Neuromuscular Electrical Stimulation Compared to Volitional Exercise for Improving Muscle Function in RheumatoidArthritis: A Randomized Pilot Study The aim of this study was to compare the feasibility and effectiveness of neuromuscular electrical stimulation (NMES) with that of high-intensity volitional resistance training for improving muscle structure and function and physical function in patients with rheumatoidarthritis (RA). We also compared pre-intervention and post-intervention values
Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoidarthritis To develop and evaluate an adjusted score for the multi-biomarker disease activity (MBDA) test to account for the effects of age, sex and adiposity in patients with RA.Two models were developed to adjust MBDA score for age, sex and adiposity, using either serum leptin concentration or BMI as proxies for adiposity. Two cohorts were studied. A cohort of 325 781 RA
Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoidarthritis: a multidatabase cohort study To investigate the rate of serious bacterial, viral or opportunistic infection in patients with rheumatoidarthritis (RA) starting tocilizumab (TCZ) versus tumour necrosis factor inhibitors (TNFi) or abatacept.Using claims data from US Medicare from 2010 to 2015, and IMS and MarketScan from 2011 to 2015, we identified adults with RA who initiated TCZ or TNFi
Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in RheumatoidArthritis: The IMAGINE-RA Randomized Clinical Trial. Whether using magnetic resonance imaging (MRI) to guide treatment in patients with rheumatoidarthritis (RA) improves disease activity and slows joint damage progression is unknown.To determine whether an MRI-guided treat-to-target strategy vs a conventional clinical treat-to-target strategy
Risk of serious infections in patients with rheumatoidarthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden To estimate (1) crude and age-and gender-adjusted incidence rates (IRs) of serious infections (SI) and (2) relative risks (RR) of SI in patients with rheumatoidarthritis (RA) initiating treatment with abatacept, rituximab or tocilizumab in routine care.This is an observational cohort study conducted in parallel in Denmark and Sweden including
Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoidarthritis Safety and efficacy of mAbs blocking the IL-6 receptor have been established in RA. This is the first analysis examining safety and tolerability of sarilumab and tocilizumab administered as single or multiple doses in patients with RA within the same study.In ASCERTAIN, patients were randomized 1: 1: 2 to 24 weeks' double-blind sarilumab 150 or 200 mg every 2 weeks s.c
Existing drugs for rheumatoidarthritis may also improve associated fatigue Existing drugs for rheumatoidarthritis may also improve associated fatigue Discover Portal Discover Portal Existing drugs for rheumatoidarthritis may also improve associated fatigue Published on 23 August 2016 doi: Biological treatments for moderate to severe rheumatoidarthritis appear to reduce fatigue as well as other symptoms. Although existing studies looking at effectiveness have focused on symptoms such as pain (...) be an important consideration for patients and prescribers. Share your views on the research. Why was this study needed? Rheumatoidarthritis affects around 400,000 people in the UK. It is an autoimmune disease in which the person’s own immune system attacks their body, in this case mainly the joints, causing inflammation, swelling, stiffness, pain and irreversible joint damage. There is no cure for rheumatoidarthritis. Treatments such as anti-inflammatory painkillers aim to relieve symptoms while drugs